Netilmicin Sulfate Injection

1 Pharmacology This product is a semi-synthetic aminoglycoside antibiotic. It has strong antibacterial activity against aerobic Gram-negative bacteria, and its antibacterial spectrum is similar to that of gentamicin. It has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, indole-negative and -positive Proteus, Klebsiella, Acinetobacter, Citrobacter, and some strains of Serratia and Enterobacter. It also has good antibacterial effects on Mycobacterium tuberculosis, atypical mycobacteria and Staphylococcus aureus (enzyme-producing and non-enzyme-producing strains). Other Gram-positive bacteria (including Streptococcus faecalis), anaerobic bacteria, Rickettsia, fungi and viruses are not sensitive to this product. This product is stable to aminoglycoside acetyltransferase AAC (3), so it can produce this enzyme. Strains resistant to kanamycin, gentamicin, tobramycin and sisomicin are sensitive to this product. This product can often achieve synergistic effects when used in combination with beta-lactams. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. 2 Toxicological animal test data indicate that this product has lower ototoxicity than gentamicin and tobramycin, and lower nephrotoxicity than gentamicin.

The main ingredient of this product is netilmicin, and its chemical name is O-3-deoxy-4-C-methyl-3-methylamino--L-arabinose pyranosyl (14)-O-[2,6-diamino-2,3,4,6-tetradeoxy--D-glyceryl-4-enyl hexopyranosyl-(16)]-2-deoxy-N3-ethyl-L-streptamine sulfate. Molecular formula: (C21H41N5O7)25H2SO4. Molecular weight: 144

This product is a colorless or almost colorless clear liquid.

1. This product is suitable for the treatment of severe infections caused by sensitive Gram-negative bacilli, such as neonatal sepsis, septicemia, central nervous system infection (including meningitis), urinary tract and reproductive system infection, respiratory tract infection, gastrointestinal tract infection, peritonitis, biliary tract infection, skin or bone infection, otitis media, sinusitis, soft tissue infection, listeriosis, etc. caused by Pseudomonas aeruginosa, Proteus (indole positive and negative), Escherichia coli, Klebsiella, Enterobacter, Serratia and Citrobacter. 2. This product can also be used in combination with other antibacterial drugs to treat staphylococcal infections, but it is often ineffective against methicillin-resistant staphylococcal infections.

1 For patients with normal renal function: Intramuscular injection or intravenous drip after dilution for adults. 1.3-2.2 mg/kg per body weight every 8 hours; or 2-3.25 mg/kg per 12 hours; for the treatment of complicated urinary tract infection, 1.5-2 mg/kg per body weight every 12 hours. The course of treatment is 7-14 days. The maximum daily dose shall not exceed 7.5 mg/kg. 1 mg/kg should be supplemented after hemodialysis. 2 For children, intramuscular injection or intravenous drip after dilution. (1) For children under 6 weeks old, 2-3 mg/kg per body weight every 12 hours; (2) For children aged 6 weeks to 12 years, 1.7-2.3 mg/kg per body weight every 8 hours; or 2.5-3.5 mg/kg per body weight every 12 hours. The course of treatment is 7-14 days.

1. Nephrotoxicity: its toxicity is mild and rare. Nephrotoxicity often occurs in patients with existing renal impairment or those who are infected with doses exceeding the usual dose; 2. Nervous system toxicity: toxic reactions to the eighth cranial nerve may occur. Compared with other commonly used aminoglycoside antibiotics, its incidence is low and the degree is also mild. It is easy to occur in patients with existing renal impairment or infected patients with excessive treatment doses and long courses of treatment. It manifests as vestibular and hearing damage symptoms, such as dizziness and hearing abnormalities, but there are no reports of deafness; 3. Others: Occasionally, headaches, general discomfort, visual impairment, palpitations, rashes, fever, vomiting and diarrhea may occur; 4. Local reactions are generally rare, and there is occasionally pain in the injection area.

Patients who are allergic to or have severe toxic reactions to this product or any aminoglycoside antibiotics are contraindicated.

Precautions for children: This product should not be used in newborns. If there is an indication for use, the dosing regimen must be adjusted under blood drug concentration monitoring. Precautions for pregnancy and lactation: This product can pass through the blood-placental barrier and enter the fetus, so it is forbidden for pregnant women. The use of this product in lactating women is not yet clear, and if this product is used, breastfeeding should be stopped.

1 Avoid using this product in combination with other nephrotoxic and neurotoxic drugs such as aminoglycoside antibiotics, vancomycin, polymyxin, strong diuretics and neuromuscular blocking drugs. 2 Mixing this product with beta-lactams (cephalosporins or penicillins) may lead to mutual inactivation. When combined use is required, it must be dripped in separate bottles; this product should not be dripped in the same bottle with other drugs.

Sealed, store in a cool place

2ml: 100,000 units

24 months

Sichuan Sunnyhope Pharmaceutical Co., Ltd.

• Founded in:

  1993-09-21

• Address:

  No. 401, 4th Floor, Building 9, No. 88, Keyuan South Road, High-tech Zone, Chengdu, Sichuan Province (production projects are limited to branches operating in the industrial park)

• Tax NO.:

  915101006217076154

• Registered Funds:

  110.5657302 yuan

• Website:

  Log in to view

• Email:

  Log in to view